Back to results
US 2016/0106827 A1Published application
V3 immunogens
AssigneesDuke University, Sloan-Kettering Institute for Cancer Research, Dana-Farber Cancer Institute, Inc.
InventorsBarton F. Haynes, Hua-xin Liao, Samuel Danishefsky, Peter Park, Joseph Sodroski, Baptiste Aussedat, Yusuf Vohra
Life of this patent
Estimating the term…
Abstract
The present invention relates, in general, to human immunodeficiency virus (HIV), and, in particular, to a vaccine for HIV-1, comprising synthetic V3 glycopeptides, and to methods of making and using same.
Claims15
A synthetic peptide comprising sequence SEQ ID NO:
- 2, 4, 6, 7, 8 or 9, wherein the peptide is glycosylated at positions Asn301 and Asn 332, and wherein the peptide is cyclic via endogenous cysteins.
A synthetic glycopeptide of the structure in FIG. 12 (peptide of SEQ ID NO:
- 8 glycosylated at positions Asn301 and Asn 332 with Man9GlcNAc2, wherein the peptide is cyclic via endogenous cysteins.
Dependencies are inferred from the claim text.